{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Acetadote",
    "query": {
      "intervention": "Acetadote"
    },
    "page_size": 10
  },
  "pagination": {
    "page": 1,
    "page_size": 10,
    "total_count": 246,
    "total_pages": 25,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Acetadote&page=2&page_size=10",
    "previous_page_url": null
  },
  "source": "remote",
  "last_synced_at": "2026-09-03T15:25:43.700Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT03120468",
      "title": "Topiramate Augmenting Strategies for the Treatment of Alcohol Use Disorder",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "EARLY_PHASE1"
      ],
      "conditions": [
        "Alcoholism"
      ],
      "interventions": [
        {
          "name": "Topiramate and N-Acetyl Cysteine",
          "type": "DRUG"
        },
        {
          "name": "Topiramate and Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Nassima Ait-Daoud Tiouririne",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 17,
      "start_date": "2017-05-01",
      "completion_date": "2019-06-30",
      "has_results": false,
      "last_update_posted_date": "2026-05-27",
      "last_synced_at": "2026-09-03T15:25:43.700Z",
      "location_count": 1,
      "location_summary": "Charlottesville, Virginia",
      "locations": [
        {
          "city": "Charlottesville",
          "state": "Virginia"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03120468"
    },
    {
      "nct_id": "NCT01339858",
      "title": "The Effect of N-Acetyl Cysteine on Cortical Erosion in Early Stage Schizophrenia",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE4"
      ],
      "conditions": [
        "Schizophrenia",
        "Psychotic Disorder NOS",
        "Schizoaffective Disorder",
        "Schizophreniform"
      ],
      "interventions": [
        {
          "name": "N-Acetyl Cysteine",
          "type": "DRUG"
        },
        {
          "name": "sugar pill",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "DRUG",
        "OTHER"
      ],
      "sponsor": "Indiana University",
      "sponsor_class": "OTHER",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "16 Years",
        "maximum_age": "35 Years",
        "sex": "ALL",
        "summary": "16 Years to 35 Years"
      },
      "enrollment_count": 60,
      "start_date": "2011-05",
      "completion_date": "2015-12",
      "has_results": true,
      "last_update_posted_date": "2019-05-08",
      "last_synced_at": "2026-09-03T15:25:43.700Z",
      "location_count": 2,
      "location_summary": "Indianapolis, Indiana",
      "locations": [
        {
          "city": "Indianapolis",
          "state": "Indiana"
        },
        {
          "city": "Indianapolis",
          "state": "Indiana"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01339858"
    },
    {
      "nct_id": "NCT01424033",
      "title": "A Clinical Trial for CTD-ILD Treatment",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2",
        "PHASE3"
      ],
      "conditions": [
        "Interstitial Lung Disease",
        "Connective Tissue Disease"
      ],
      "interventions": [
        {
          "name": "N-Acetylcysteine",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "University of Michigan",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 5,
      "start_date": "2011-12",
      "completion_date": null,
      "has_results": true,
      "last_update_posted_date": "2017-04-06",
      "last_synced_at": "2026-09-03T15:25:43.700Z",
      "location_count": 1,
      "location_summary": "Ann Arbor, Michigan",
      "locations": [
        {
          "city": "Ann Arbor",
          "state": "Michigan"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01424033"
    },
    {
      "nct_id": "NCT03500627",
      "title": "A Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of OP-101 After Intravenous Administration in Healthy Volunteers",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Healthy"
      ],
      "interventions": [
        {
          "name": "OP-101",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Orpheris, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "65 Years",
        "sex": "ALL",
        "summary": "18 Years to 65 Years"
      },
      "enrollment_count": 8,
      "start_date": "2018-03-30",
      "completion_date": "2018-07-20",
      "has_results": false,
      "last_update_posted_date": "2018-09-17",
      "last_synced_at": "2026-09-03T15:25:43.700Z",
      "location_count": 1,
      "location_summary": "Cincinnati, Ohio",
      "locations": [
        {
          "city": "Cincinnati",
          "state": "Ohio"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03500627"
    },
    {
      "nct_id": "NCT00585559",
      "title": "Acetaminophen in aSAH to Inhibit Lipid Peroxidation and Cerebral Vasospasm",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Aneurysmal Subarachnoid Hemorrhage",
        "Cerebral Vasospasm"
      ],
      "interventions": [
        {
          "name": "Placebos for acetaminophen and N-acetylcysteine",
          "type": "DRUG"
        },
        {
          "name": "APAP 1 gm every 6 hours and N-acetylcysteine placebo",
          "type": "DRUG"
        },
        {
          "name": "NAC IV infusion at 0.5 gm hourly and APAP placebo",
          "type": "DRUG"
        },
        {
          "name": "APAP 1 gm q6 hours, plus NAC IV infusion at 0.5 gm hourly",
          "type": "DRUG"
        },
        {
          "name": "APAP 1.5 gm q6 hours, plus NAC IV infusion at 0.5 gm hourly",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Vanderbilt University Medical Center",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "20 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "20 Years and older"
      },
      "enrollment_count": 44,
      "start_date": "2007-04",
      "completion_date": "2023-10-26",
      "has_results": true,
      "last_update_posted_date": "2025-04-18",
      "last_synced_at": "2026-09-03T15:25:43.700Z",
      "location_count": 1,
      "location_summary": "Nashville, Tennessee",
      "locations": [
        {
          "city": "Nashville",
          "state": "Tennessee"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00585559"
    },
    {
      "nct_id": "NCT00493727",
      "title": "Use of Mucomyst to Ameliorate Oxidant Stress in Diabetics With Proteinuria",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "Diabetes",
        "Proteinuria"
      ],
      "interventions": [
        {
          "name": "N-acetylcysteine(Mucomyst)",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "US Department of Veterans Affairs",
      "sponsor_class": "FED",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "80 Years",
        "sex": "ALL",
        "summary": "18 Years to 80 Years"
      },
      "enrollment_count": 15,
      "start_date": "2006-09",
      "completion_date": "2007-12",
      "has_results": false,
      "last_update_posted_date": "2008-05-19",
      "last_synced_at": "2026-09-03T15:25:43.700Z",
      "location_count": 1,
      "location_summary": "Dayton, Ohio",
      "locations": [
        {
          "city": "Dayton",
          "state": "Ohio"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00493727"
    },
    {
      "nct_id": "NCT01907061",
      "title": "Acute Renal Failure Post Liver Transplantation",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "Acute Renal Failure"
      ],
      "interventions": [
        {
          "name": "N-acetylcysteine",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Baylor Research Institute",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "71 Years",
        "sex": "ALL",
        "summary": "18 Years to 71 Years"
      },
      "enrollment_count": 30,
      "start_date": "2007-07",
      "completion_date": "2014-07",
      "has_results": false,
      "last_update_posted_date": "2020-02-21",
      "last_synced_at": "2026-09-03T15:25:43.700Z",
      "location_count": 1,
      "location_summary": "Dallas, Texas",
      "locations": [
        {
          "city": "Dallas",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01907061"
    },
    {
      "nct_id": "NCT02335060",
      "title": "N-acetylcysteine Effects on Tetrahydrocannabinol",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "EARLY_PHASE1"
      ],
      "conditions": [
        "Healthy"
      ],
      "interventions": [
        {
          "name": "Delta-9-THC",
          "type": "DRUG"
        },
        {
          "name": "N-acetylcysteine",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Yale University",
      "sponsor_class": "OTHER",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "55 Years",
        "sex": "ALL",
        "summary": "18 Years to 55 Years"
      },
      "enrollment_count": 5,
      "start_date": "2014-05-02",
      "completion_date": "2014-09-16",
      "has_results": false,
      "last_update_posted_date": "2022-01-31",
      "last_synced_at": "2026-09-03T15:25:43.700Z",
      "location_count": 1,
      "location_summary": "West Haven, Connecticut",
      "locations": [
        {
          "city": "West Haven",
          "state": "Connecticut"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02335060"
    },
    {
      "nct_id": "NCT00136825",
      "title": "Effectiveness of N-acetylcysteine in Treating Cocaine Dependent Individuals - 1",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Cocaine-Related Disorders"
      ],
      "interventions": [
        {
          "name": "N-Acetylcysteine",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "National Institute on Drug Abuse (NIDA)",
      "sponsor_class": "NIH",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "45 Years",
        "sex": "ALL",
        "summary": "18 Years to 45 Years"
      },
      "enrollment_count": 17,
      "start_date": "2003-03",
      "completion_date": "2005-09",
      "has_results": false,
      "last_update_posted_date": "2017-01-12",
      "last_synced_at": "2026-09-03T15:25:43.700Z",
      "location_count": 1,
      "location_summary": "Charleston, South Carolina",
      "locations": [
        {
          "city": "Charleston",
          "state": "South Carolina"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00136825"
    },
    {
      "nct_id": "NCT06727422",
      "title": "Efficacy of Rifaximin With NAC in IBS-D",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "IBS (Irritable Bowel Syndrome)",
        "IBS-D (Diarrhea-predominant)"
      ],
      "interventions": [
        {
          "name": "rifaximin 66mg + N-acetylcysteine 560mg three times daily",
          "type": "DRUG"
        },
        {
          "name": "RNIB21 containing rifaximin 132mg + N-acetylcysteine 560mg three times daily",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Mark Pimentel, MD",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 225,
      "start_date": "2026-02-04",
      "completion_date": "2027-01-01",
      "has_results": false,
      "last_update_posted_date": "2026-04-20",
      "last_synced_at": "2026-09-03T15:25:43.700Z",
      "location_count": 1,
      "location_summary": "Los Angeles, California",
      "locations": [
        {
          "city": "Los Angeles",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06727422"
    }
  ]
}